Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aripiprazole versus placebo in children and adolescents with Tourette's disorder
NL-OMON36846Phase 3Withdrawn
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Jan 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Tourette syndrome (TS) comparing Abilify once daily with Placebo once daily (2 arms). Primary endpoint: Change from baseline to endpoint in YGTSS Total Tic Score. Planned start Jan 2013; status: withdrawn.
02
Drugs
aripiprazole
03
Conditions
Tourette syndrome (TS)
Beyond the preview
Go deeper on NL-OMON36846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36846.